欢迎来到苏州第三制药厂有限责任公司!
您的位置 : 首页 - 新闻资讯 - 行业新闻

联系我们

  • 苏州第三制药有限责任公司

    地址 : 江苏省苏州市吴江区汾湖高新技术产业开发区金字路8号

    邮编 : 215001

    人事行政部 :

    电话 :(0512)8287 2058

    E-mail : hr@uni-cent.com

    销售部 :

    电话 :(086)512-6693 6472

    手机 :189 1409 1973

    传真 :(086)512-6752 9886

    E-mail :3250139710@qq.com

Zoomlion strives to lead the domestic small cephalosporins industry
发布时间 : 2021-07-13 新闻来自 : City business daily Wujiang reader No.131 W2 Edition
Suzhou Zhonglian Chemical Pharmaceutical Co., Ltd. has been rooted in FenHu high tech Zone for nearly ten years. Now, the company not only leads its peers in the field of cephalosporins, but also extends its industrial chain to the field of preparations through transformation and upgrading, becoming the leader of domestic high-end small cephalosporins pharmaceutical industry.

The R & D center of Zoomlion pharmaceutical is set up in the science and technology innovation park of FenHu high tech Zone. Today, 18 kinds of cephalosporins have passed the new GMP certification, among which cefaclor occupies 70% of the domestic market, ranking first in the industry. Such a high market share benefits from the dual advantages of technology and cost, but for Zoomlion, the most fundamental advantage is the talent advantage“ Technological advantage is very important. An enterprise should have its competitiveness. The core competitiveness lies in your technology and the technology of your talent pool. This is very important. Today, the senior talent team of Zoomlion has more than 30 people, including 4 senior engineers and 4 people with graduate degree or above. In addition, it plans to establish academician workstation and national "thousand talents plan" workstation through cooperation with colleges and universities such as Jiangsu University College of pharmacy and Shanghai Jiaotong University Mr. Liu, assistant general manager of Zoomlion Chemical Pharmaceutical Co., Ltd., said.



In recent years, the company's performance has increased year by year, and the benefits are remarkable. However, the company's management clearly realizes that API is still a relatively low-end product in the pharmaceutical industry. To further develop the enterprise, only by upgrading and transformation, becoming specialized, bigger and stronger, can it achieve sustainable development. This year, Zoomlion invested 200 million yuan to build a new plant. On the one hand, it hopes to make more sophisticated production of API and sell it abroad to India, South America and other countries. On the other hand, it strives to make new breakthroughs in preparation and realize leapfrog development.
< >